Pro-GM food scientist 'threatened editor'

GM food: special report The Guardian

Laurie Flynn and Michael Sean Gillard
Monday November 1, 1999

The editor of one of Britain's leading medical
journals, the Lancet, says he was threatened by a
senior member of the Royal Society, the voice of
the British science establishment, that his job
would be at risk if he published controversial
 research questioning the safety of genetically
fied foods.

 Richard Horton declined to name the man who
telephoned him. But the Guardian has identified
 him as Peter Lachmann, the former
vice-president and biological secretary of the
Royal Society and president of the Academy of
Medical Sciences.

The Guardian has been told that an influential
 group within the Royal Society has set up what
 appears to be a "rebuttal unit" to push a
 pro-biotech line and counter opposing scientists
 and environmental groups.

 Dr Horton said he was called at his office in
central London on the morning of Wednesday
October 13, two days before the Lancet published
a research paper by Arpad Pusztai, the scientist
 at the centre of the GM controversy.

Dr Horton, editor of the Lancet since 1995, said
the phone call began in a "very aggressive
 manner". He said he was called "immoral" and
accused of publishing Dr Pusztai's paper which he
"knew to be untrue".

 Towards the end of the call Dr Horton said the
caller told him that if he published the Pusztai
paper it would "have implications for his
personal position" as editor. The Lancet is owned
 by Reed Elsevier, one of Europe's largest
scientific publishing houses.

 At the end of the call Dr Horton, 37, said he
immediately informed his colleagues and named
the caller.

Prof Lachmann, a professor of immunology at
Cambridge and a Royal Society fellow for 17
years, confirmed that he rang Dr Horton on
October 13 to discuss his "error of judgment" in
deciding to publish the paper.

 He said he called Dr Horton after he had been
 emailed, "probably by the Royal Society", a proof
of the paper.

However, Prof Lachmann, 67, "categorically
denies" making any threat to Dr Horton during the
 call. "This is absolute rubbish, it would never
 have crossed my mind," he said. "I didn't accuse
 him of being immoral. I said there were moral
 difficulties about publishing bad science. I think I
 probably suggested to him that he knew the
 science was very bad. They [the Lancet] knew it
 was bad science, whether you call that untrue or
 not, I don't think I used the word untrue."

 Prof Lachmann's call to Dr Horton was preceded
 by a series of controversial interventions by the
 society on the Pusztai affair. While
 vice-president of the society, Prof Lachmann
 chaired a special working group on GM plants for
 food use last year which endorsed their "potential
 for real benefits" but recognised the need for
 further research and monitoring. The Royal
 Society says that its report is now being used as a
 "source document" by the government.

 The Lachmann group report was published in
 September 1998, a month after Dr Pusztai first
 expressed his concerns on British TV about their
 safety, questioning government regulatory
 procedures. Dr Pusztai's employer, the Rowett
 Institute, had authorised the interview, but it
 seized his data, forced him to retire and banned
 him from speaking out.

 In February, Prof Lachmann was one of the 19
 Royal Society fellows who attacked Dr Pusztai's
 work in an open letter. He and other key Royal
 Society fellows have since been at the forefront of
 defending GM technology and extolling its ability
 to solve world hunger and provide safer food and
 medicines.

 His extensive CV includes a recent consultancy to
 Geron Biomed, which markets the animal cloning
 technology behind Dolly the sheep, and a
 non-executive directorship for the biotech
 company Adprotech. Prof Lachmann is also on the
 scientific advisory board of the pharmaceutical
 giant SmithKline Beecham, which invests heavily
 in biotechnology. He denies any conflict of
 interest, arguing that his expertise in the area
 qualifies him to comment.

 The first intervention came in March when the
 Royal Society, which does not normally conduct
 peer reviews, took the unusual decision to
 scrutinise Dr Pusztai's work.

 A group of reviewers, whom the society refuses to
 name, concluded after examining incomplete data
 that it appeared to be "flawed in many aspects of
 design, execution and analysis".

 Dr Horton wrote a Lancet editorial that month
 accusing the Royal Society of "breathtaking
 impertinence". Prof Lachmann, who was not
 involved in this peer review, nevertheless
 countered with a letter attacking the journal's
 position as "absurd". Dr Horton published the
 letter in July. At the same time, the Lancet was
 considering whether to peer review and publish
 the now famous paper by Dr Pusztai and Stanley
 Ewen on the effect on the gut of rats fed GM
 potatoes.

 Dr Horton was also considering publishing a
 second research paper by another team of
 scientists. They had looked at the same GM protein
 used in Dr Pusztai's potatoes and found that it
 binds to human white blood cells. The health
 implications must be further researched before
 the GM protein is allowed into the food chain, the
 paper recommended.

 Dr Horton said he never expected what would
 follow from his decision to promote scientific
 debate by publishing both papers. He said there
was intense pressure on the Lancet from all
quarters, including the Royal Society, to suppress
 publication. The campaign, he said, was "worthy
 of Peter Mandelson".

 The Guardian has learned that these interventions
 are taking place in an unusual context. According
 to a source the Royal Society science policy
 division is being run as what appears to be a
 rebuttal unit. The senior manager of the division
 is Rebecca Bowden, who coordinated the highly
 critical peer review of Dr Pusztai's work. She
 joined the society in 1998, from the government
 biotechnology unit at the department of the
 environment, which controls the release of
 genetically modified organisms.

 The rebuttal unit is said by the source to operate a
 database of like-minded Royal Society fellows who
 are updated by email on a daily basis about GM
 issues. The aim of the unit, according to the
 source, is to mould scientific and public opinion
 with a pro-biotech line. Dr Bowden confirmed
 that her main role is to coordinate biotech policy
 for the society, reporting to the president, Sir
 Aaron Klug. However, she and Sir Aaron denied it
 was a spin-doctoring operation.

 In May a leaked government memo outlined how
 its office of science and technology was compiling
 a list of eminent scientists who were on message
 to rebut criticism and underwrite the
 government's unequivocal pro-biotech line.

 The Guardian has established that the Royal
 Society was involved in trying to prevent
 publication of the Pusztai paper. This
 intervention intensified when it learnt the paper
 had been peer reviewed for the Lancet by six
 scientists, Dr Horton told the Guardian.

 The only reviewer arguing against publication
 was John Pickett of the government-funded
 Institute of Arable Crops Research.

 Prof Pickett said that when he realised that Dr
 Pusztai's paper had been accepted for publication,
 he took his concerns to the Royal Society' s
 biological secretary who told him the society was
 already preparing a press release.

 Five days before the Lancet published, an article
 appeared in a national newspaper in which Prof
 Pickett broke the protocols of peer review and
 publicly attacked the Lancet for agreeing to
 publish the Pusztai paper. Two days after the
 spoiler article appeared, Prof Lachmann made his
 phone call to the editor of the Lancet.

 Dr Horton said the society had acted like a star
 chamber throughout the Pusztai affair. "The Royal
 Society has absolutely no remit to conduct that
 sort of inquiry."

 Sir Aaron said he knew nothing about the phone
 call to Dr Horton and whoever spoke to the Lancet
 editor was not doing so on the society's behalf.
 However, he confirmed that the society had a
 proof of the Pusztai paper before the Lancet
 published it.


Home